Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • 12 Nov 2015

    Agenus R&D Update to Be Held on November 19, 2015
    Read More


  • 05 Nov 2015

    Agenus to Acquire Antibody Manufacturing Capability, Expands Antibody Discovery and adds Cell Line Development Capabilities with Three Separate Transactions
    Read More


  • 27 Oct 2015

    Agenus Reports Third Quarter 2015 Financial Results
    Read More


  • 20 Oct 2015

    Agenus to Report Third Quarter 2015 Financial Results on October 27, 2015; Conference Call to Follow
    Read More


  • 09 Sep 2015

    Agenus Inc. Completes $115 Million Non-Dilutive Royalty Transaction with Oberland Capital
    Read More


  • 08 Sep 2015

    Agenus to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
    Read More